// App-Quantinova.ai

: SEQUENCING OF NOVEL AGENTS IN B-CELL ACUTE LYMPHOCYTIC LEUKEMIA (ALL): BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN HAVE COMPARABLE EFFICACY AS FIRST OR SECOND NOVEL AGENT THERAPY IN ALL

Researchers

Presenter

  • Talha Badar

Principal Investigators

  • Shira Dinner

  • Michaela Liedtke

  • Madelyn Burkart

  • Rory Shalis

  • Shukaib Arsalan

  • Muhammad Ali Khan

  • Ibrahim Aldoss

  • Caitlin Siebenaller

  • Elizabeth Schultz

  • Mehrdad Hefazi

  • Ilana Yurkiewicz

  • Nikolai Podoltsev

  • Anand Patel

  • Emily Curran

  • Eric Kuo

  • Amy Wang

  • Suresh Balasubramanian

  • Jay Yang

  • Ryan Mattison

  • Mark Litzow

  • Martha Wadleigh

  • Anjali Advani

  • Ehab Atallah

Medical Centers

  • Division of Hematology/Oncology, Medical College of Wisconsin,Milwaukee, WI,Stati Uniti

  • Division of Hematology/Oncology, Medical College of Wisconsin,Milwaukee, WI,Stati Uniti

  • Rush University Medical Center, Chicago, Illinois, United States

  • Hematology and Oncology,University of Stanford,Stanford,United States

  • Hematology and Oncology,Northwestern University,Chicago,United States

  • Hematology and Oncology,Yale University,New Haven,United States

  • City of Hope, Duarte, United States

  • Neurology, Medical College of Wisconsin, Milwaukee, United States

  • Cleveland Clinic, Cleveland, United States,

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Mayo Clinic, Rochester, United States

  • University of Stanford,Stanford,United States

  • Yale University, New Haven, Connecticut, United States

  • University of Chicago, Chicago, IL, United States

  • karmanos Cancer Center,Michigan,United States

  • Karmano Cancer Center, Detroit, Michigan, United States

  • University of Wisconsin, Madison, Wisconsin, United States

  • Dana-Farber Cancer Institute, Boston, MA, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved